YKYana V. Kozyr

Yana V. Kozyr

*This is an algorithmically generated author record based on publicly available information.

Yana V. Kozyr has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Experience with the use of a pulsed dye laser in the treatment of patients with palmoplantar psoriasis

    by Ya. V. Kozyr, M. S. Petrova, A. A. Khotko, E. A. Inyukhina

    Palmoplantar psoriasis is a socially significant form of chronic dermatosis leading to a marked decrease in the quality of life and limitation of work activity. The search for effective and safe treatment methods, especially in the presence of contraindications to systemic therapy, remains relevant. Objective. To evaluate the clinical efficacy and tolerability of pulsed dye laser in patients with palmoplantar psoriasis. Material and methods. Two clinical cases are described. The first patient (61 years old) received a combination of topical therapy (salicylic acid, betamethasone) and a course of pulsed dye laser. The second case (a patient with controlled type 2 diabetes mellitus and intolerance to methotrexate) was treated with pulsed dye laser after discontinuation of the cytostatic agent. Efficacy was assessed by the dynamics of the palmoplantar psoriasis severity index (PPASI). Results. Both patients showed significant positive dynamics. In the first case, the PPASI score decreased from 18 points to 1 point. In the second case, it decreased from 15 points to 0.5 points. There were no side effects from phototherapy. Conclusion. Pulsed dye laser demonstrated high efficacy and good tolerability in the treatment of palmoplantar psoriasis. This method can be considered an optimal treatment option, especially in the presence of comorbid conditions that limit the use of systemic medications.

  • Open Access

    Analysis of clinical and anamnestic data in patients with psoriasis

    by Ya. V. Kozyr, L. S. Kruglova

    Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation of keratinocytes and immune dysregulation. It is associated with genetic predisposition, autoimmune disorders, comorbid pathology, mental and psychological diseases, and environmental factors. The objective of this study was to study the prevalence of palmar-plantar psoriasis in a general cohort of patients with psoriasis and to identify the main risk factors for the development of this phenotype of dermatosis. For this purpose, the analysis of clinical and anamnestic data was carried out in patients with a diagnosis of psoriasis. In total, the study group included 757 patients with various phenotypes of psoriasis, whose data were analyzed in the general cohort and further based on the division of patients by the presence of LPP (2 groups), while comparing all clinical and anamnestic data in the context of the presence of lesions in the localization of the palms and soles.

  • Diseases of cardiovascular system in patients with severe and moderatesevere forms of psoriasis

    by A. A. Hotko, M. Yu. Pomazanova, Y. V. Kozyr

    Psoriasis is one of the most common chronic recurrent dermatoses, which is not limited to skin lesions, leading to a violation of the functions of various body organ systems. The article presents the results of the analysis of the medical histories of patients of Clinical dermatovenerologic dispensary (Krasnodar Region of Russia) with moderate-severe and severe forms of psoriasis and concomitant cardiological pathology. The article presents data from 70 case histories of patients with moderate to severe psoriasis, the analysis of which shows the clinical and practical significance of comorbidity of psoriasis. From the analysis, we conclude that there is a direct relationship between the severity of the course of the cutaneous pathological process and the aggravation of the cardiological diagnosis. The higher the severity of psoriasis, the higher the risk of developing acute coronary syndrome, myocardial infarction and other cardiac pathology.


  • Certolizumab pegol in treatment of psoriasis and psoriatic arthritis: patient profiles, inspection, monitoring of safety

    by A. A. Khotko, M. Yu. Pomazanova, Ya. V. Kozyr

    Цертолизумаба пэгол в лечении псориаза и псориатического артрита. Профиль пациента, обследование, мониторинг эффективности и переносимости

  • Open Access

    Multimorbidity in Pediatric Dermatology: Clinical Case

    by Nikolay N. Murashkin, Alexander I. Materikin, Eduard T. Ambarchian, Roman V. Epishev, Leonid A. Opryatin, Roman A. Ivanov, Daria S. Kukoleva, Daria G. Kuptsova, Alexander A. Pushkov, Marina Yu. Pomazanova, et al.

    Background. Nowadays, dermatoses with mixed clinical picture and resistant to classical management become more common. The presence of various genetic disorders typical for most chronic dermatoses may indicate possible combination of several nosologies.Clinical Case Description. The article presents the clinical case of multimorbid condition in 10 years old patient who has nucleotide variants in CARD14 and EXPH5 genes. Mutations in CARD14 gene are typical for patients with type 2 psoriasis and pityriasis rubra pilaris (autosomal dominant type), while mutations in EXPH5 gene are typical for patients with non-specific epidermolysis bullosa (autosomal recessive type). Mutation in the TGM1 gene that is described in patients with congenital ichthyosis (autosomal recessive type), pathogenic mutations in KRT74 gene typical for ectodermal dysplasia, hypotrichosis and uncombable hair syndrome, and mutations in the KRT86 gene typical for monilethrix were also revealed. Medical history taking and histological examination as well as clinical data evaluating are crucial for correct diagnosis. They allow to understand the absence of the such manifestations in relatives and reveal various pathological processes in the epidermis. Molecular genetic testing with new generation sequencing (NGS) helps to finally establish the diagnosis and determine the further tactics for patient management.Conclusion. Multidisciplinary approach and use of high-technology methods of examination and treatment (such as molecular genetic testing and biological therapy) are required for final diagnosis in severe forms of chronic dermatosis resistant to treatment and for decision on correct tactics for the further management of such patients.

  • Open Access

    Psoriasis Comorbidities in Childhood

    by Nikolay N. Murashkin, Larisa S. Kruglova, Iuliia A. Kovalenko, Eduard T. Ambarchian, Roman V. Epishev, Alexander I. Materikin, Leonid A. Opryatin, Roman A. Ivanov, Daria S. Kukoleva, Daria G. Kuptsova, et al.

    Psoriasis is multifactorial systemic disease characterized by excessive hyperkeratosis due to impaired keratinocytes proliferation and differentiation. This disease often manifests in childhood and it is usually associated with the development of comorbid conditions some of which are combined by the term «psoriatic march» (obesity, metabolic syndrome, etc.). The course of psoriasis and related comorbidities in children has several specific features that determine topicality of studying all the aspects of clinical diagnosis and prevention in childhood. The article summarizes recent ideas on the prevalence, pathogenesis features and early diagnosis of comorbid diseases in children with psoriasis.


  • Open Access

    Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study

    by Nikolay N. Murashkin, Eduard T. Ambarchian, Roman V. Epishev, Alexander I. Materikin, Leonid A. Opryatin, Roman A. Ivanov, Daria S. Kukoleva, Marina Y. Pomazanova, Daria G. Kuptsova, Yana V. Kozyr, et al.

    Background. The study of psoriasis biological therapy aspects in children has certain topicality due to the small number and disunity of individual observations and the lack of special registers for pediatric patients.Objective. Our aim was to study ustekinumab efficacy and safety in children with plaque (PP), erythrodermic (EP) and palmoplanar (PPP) forms of psoriasis.Methods. The analysis of ustekinumab efficacy and safety has been carrying out for 1 year. The evaluation of therapy efficacy was based on definition of improvement of PASI scores (PASI 75, PASI 90 and PASI 100) on the 16th, 28th, 40th and 52nd weeks of follow-up and children's dermatology life quality index (CDLQI). Ustekinumab therapy safety analysis was based on registration and evaluation of adverse effects. Results. The study included 67 children with PP, EP and PPP aged 12 to 18 years. PP group results: the PASI 75 response at the 52nd week of therapy was observed in 35 children (100%), PASI 90 — in 33 (94%), PASI 100 — in 30 (86%). EP group results: 10 patients (56%) have reached PASI 75 on the 16th week, while none of patients have improved to PASI 90 and PASI 100 scores. The PASI 75 response at the 52nd week of therapy was observed in 18 children (100%), PASI 90 — in 17 (94%), PASI 100 — in 7 (39%). Only 1 patient (7%) with PPP has showed the score decrease to PASI 75 on the 16th week. Adverse effects were reported in 2 patients.Conclusion. Ustekinumab is the effective and safe treatment for moderate and severe forms of PP and EP in children, and it can also be considered as one of the alternative methods for PPP treatment in pediatrics.